HSBC set a €84.00 ($97.67) price objective on Carl Zeiss Meditec (ETR:AFX) in a research note issued to investors on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
AFX has been the subject of several other reports. Hauck & Aufhaeuser set a €92.50 ($107.56) price target on shares of Carl Zeiss Meditec and gave the stock a buy rating in a report on Monday, April 15th. Nord/LB set a €92.00 ($106.98) price target on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Wednesday, May 8th. Independent Research set a €77.50 ($90.12) price target on shares of Carl Zeiss Meditec and gave the stock a sell rating in a report on Tuesday, May 7th. Berenberg Bank set a €80.00 ($93.02) price target on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Monday, May 13th. Finally, Deutsche Bank set a €71.00 ($82.56) price target on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a report on Tuesday, February 12th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of €78.25 ($90.99).
Carl Zeiss Meditec stock opened at €85.50 ($99.42) on Monday. The company has a market capitalization of $7.65 billion and a PE ratio of 59.62. The company has a current ratio of 4.11, a quick ratio of 3.09 and a debt-to-equity ratio of 4.55. Carl Zeiss Meditec has a fifty-two week low of €57.60 ($66.98) and a fifty-two week high of €90.60 ($105.35).
About Carl Zeiss Meditec
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.